ZA200700368B - Retinal derivatives and methods for the use thereof for the treatment of visual disorders - Google Patents

Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Info

Publication number: ZA200700368B
Authority: ZA; South Africa
Prior art keywords: treatment; methods; visual disorders; retinal derivatives; retinal
Prior art date: 2004-06-18

Application number

ZA200700368A

Other languages

English (en)

Inventor

Palczewski Krzysztof

Batten Matthew

Original Assignee

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-18

Filing date

2005-06-20

Publication date

2008-10-29

2005-06-20 Application filed by Univ Washington filed Critical Univ Washington

2008-10-29 Publication of ZA200700368B publication Critical patent/ZA200700368B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Ophthalmology & Optometry (AREA)
Physiology (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200700368A 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders ZA200700368B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US58088904P	2004-06-18	2004-06-18

Publications (1)

Publication Number	Publication Date
ZA200700368B true ZA200700368B (en)	2008-10-29

Family

ID=35782277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200700368A ZA200700368B (en)	2004-06-18	2005-06-20	Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Country Status (26)

Country	Link
US (8)	US7951841B2 (no)
EP (5)	EP2397131B1 (no)
JP (2)	JP5166026B2 (no)
KR (4)	KR101490145B1 (no)
CN (2)	CN102976937B (no)
AU (1)	AU2005257997B2 (no)
BR (1)	BRPI0511396B1 (no)
CA (2)	CA2931917A1 (no)
CY (2)	CY1114873T1 (no)
DK (2)	DK1765322T3 (no)
ES (4)	ES2752924T3 (no)
HR (1)	HRP20140116T1 (no)
HU (1)	HUE036596T2 (no)
IL (4)	IL180078A (no)
IN (1)	IN2012DN09335A (no)
LT (1)	LT2397133T (no)
MX (2)	MX359668B (no)
NO (1)	NO339969B1 (no)
NZ (2)	NZ552080A (no)
PL (2)	PL2397133T3 (no)
PT (2)	PT1765322E (no)
RS (1)	RS53178B (no)
RU (2)	RU2408578C2 (no)
SI (2)	SI1765322T1 (no)
WO (1)	WO2006002097A2 (no)
ZA (1)	ZA200700368B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040242704A1 (en) *	2003-03-14	2004-12-02	University Of Washington, Techtransfer - Invention Licensing	Stabilized mutant opsin proteins
EP2397131B1 (en)	2004-06-18	2019-09-11	University of Washington	Retinal derivatives and methods for the use thereof for the treatment of visual disorders
GEP20084520B (en)	2004-06-23	2008-10-27	Sirion Therapeutics Inc	Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
CN102240278A (zh) *	2004-12-08	2011-11-16	矫正诊疗公司	治疗与视黄醇有关的疾病的方法、分析和组合物
WO2008013983A2 (en) *	2006-07-27	2008-01-31	University Of Florida Research Foundation, Inc.	Opsin stabilizing compounds and methods of use
AU2007277033A1 (en) *	2006-07-27	2008-01-31	University Of Florida Research Foundation, Inc.	Compositions and methods for treating or preventing ophthalmic disease
WO2008063768A2 (en) *	2006-10-12	2008-05-29	Case Western Reserve University	Compositions and methods for treating metabolic diseases
CN101686665B (zh) *	2007-04-20	2014-04-23	奥克塞拉有限公司	用于治疗眼科疾病和紊乱的苯乙烯基衍生化合物
AU2015200520B2 (en) *	2008-02-11	2017-02-09	University Of Washington	Methods for the treatment and prevention of age-related retinal dysfunction
CA2714530C (en) *	2008-02-11	2018-09-25	University Of Washington	Methods for the treatment and prevention of age-related retinal dysfunction
US8529907B2 (en) *	2008-04-29	2013-09-10	Nikken Sohonsha Corporation	Methods of treating ophthalmic disorders
IN2012DN00352A (no)	2009-06-16	2015-08-21	Bikam Pharmaceuticals Inc
US20120178806A1 (en)	2009-09-15	2012-07-12	Qlt Inc.	Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
CA2783699C (en)	2009-12-08	2019-01-15	Case Western Reserve University	Primary amine compounds for treating ocular disorders
US8889660B2 (en)	2010-01-20	2014-11-18	Case Western Reserve University	Methods for treating obesity or an obesity related condition
KR20180043846A (ko)	2010-04-19	2018-04-30	노벨리언 테라퓨틱스 인코포레이티드	내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료 요법 및 방법
CN103384469B (zh) *	2010-11-05	2016-06-15	斯坦福大学托管董事会	光控cns功能障碍
US10226536B2 (en) *	2011-11-28	2019-03-12	Case Western Reserve University	Polysaccharide therapeutic conjugates
CA2865935C (en) *	2012-03-01	2021-12-14	Qlt Inc.	Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US20150038582A1 (en) *	2012-03-01	2015-02-05	Qlt Inc.	Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US9730941B2 (en)	2012-06-07	2017-08-15	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for the inhibition of Pin1
US20150119388A1 (en) *	2012-06-15	2015-04-30	The Children's Hospital Philadelphia	Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
US10471118B2 (en)	2014-05-30	2019-11-12	Case Western Reserve University	Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en)	2014-06-18	2021-09-28	Case Western Reserve University	Compositions and methods for the delivery of nucleic acids
WO2016011265A2 (en)	2014-07-17	2016-01-21	Beth Israel Deaconess Medical Center, Inc.	Biomarkers for pin1-associated disorders
US10925980B2 (en)	2014-08-04	2021-02-23	Case Western Reserve University	Molecular probes and methods of use
US10548864B2 (en)	2015-03-12	2020-02-04	Beth Israel Deaconess Medical Center, Inc.	Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en)	2015-06-18	2022-08-09	Case Western Reserve University	Compositions and methods for the delivery of nucleic acids
US12060318B2 (en)	2015-10-09	2024-08-13	Case Western Reserve University	Compositions and methods for the delivery of nucleic acids
NZ748179A (en) *	2016-04-28	2025-08-29	Spark Therapeutics Inc	Relative potency assay for viral vector encoding isomerohydrolases
US20250161254A1 (en) *	2022-02-04	2025-05-22	New York University	Use of retinoids for treatment of atrial fibrillation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB797977A (en) *	1956-01-16	1958-07-09	Hoffmann La Roche	Vitamin-a esters and a process for the manufacture thereof
US3196048A (en)	1961-12-19	1965-07-20	Exxon Research Engineering Co	Cathode catalyst for fuel cells
US3196078A (en)	1962-01-30	1965-07-20	Ortho Pharma Corp	Process for combating retinits pigmentosa
US3517067A (en)	1964-02-11	1970-06-23	Eastman Kodak Co	Syntheses of quaternary phosphonium salts
DE2300107C2 (de) *	1973-01-03	1982-03-11	Basf Ag, 6700 Ludwigshafen	Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) *	1974-12-03	1976-06-16	Basf Ag	4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja)	1985-05-28	1986-12-05	Taisho Pharmaceut Co Ltd	レチノイド誘導体
US5310764A (en)	1992-05-08	1994-05-10	Steven Baranowitz	Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) *	1993-06-02	1994-12-13	Lion Corp	安定な低眼刺激性ビタミンａ類可溶化点眼剤
CA2185699A1 (en)	1994-04-04	1995-10-12	William R. Freeman	Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) *	1994-06-29	1998-03-20	Красноярская государственная медицинская академия	Способ лечения близорукости
JPH08198746A (ja) *	1995-01-18	1996-08-06	Lion Corp	可溶化点眼剤
US5837728A (en)	1995-01-27	1998-11-17	Molecular Design International	9-cis retinoic acid esters and amides and uses thereof
US5489611A (en)	1995-02-10	1996-02-06	Warner-Lambert Company	Method for lowering plasma levels of lipoprotein (a)
AP789A (en) *	1995-04-03	1999-12-03	Johnson & Johnson Consumer Products Inc	Skin care compositions containing retinoids and liposomes.
US5620970A (en) *	1995-06-05	1997-04-15	Alcon Laboratories, Inc.	Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) *	1996-04-25	1998-02-10	Elizabeth Arden Co., Division Of Conopco, Inc.	Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en)	1997-08-23	1999-04-14	Werner Bollag	Treatment of cell-mediated immune diseases
US6391924B1 (en)	1997-12-10	2002-05-21	Hampar Karageozian	Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en)	1998-07-16	2003-04-22	Gentrix Llc	Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en)	1999-05-06	2002-04-16	The President & Fellows Of Harvard College	Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en)	1999-08-06	2001-10-09	Alcon Universal Ltd.	Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
JP2003529567A (ja)	2000-03-10	2003-10-07	インサイト・ビジョン・インコーポレイテッド	後眼部眼疾患を治療および予防する方法と組成物
US20020028849A1 (en)	2000-04-18	2002-03-07	Godkin James D.	Use of retinol in assisted-reproduction protocols
US6696069B2 (en)	2000-06-30	2004-02-24	Unilever Home & Personal Care Usa, Division Of Conopco, Inc.	Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
EP1261623B1 (en)	2001-01-11	2009-11-04	Chebigen Inc.	New retinol derivatives, the method of preparations and the uses thereof
AU2002240141A1 (en)	2001-01-26	2002-08-06	Steven Baranowitz	Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en)	2001-02-19	2001-04-04	King S College London	Method
CA2442670A1 (en)	2001-04-13	2002-10-24	The Trustees Of The University Of Pennsylvania	Method of treating or retarding the development of blindness
EP1476147A4 (en) *	2002-01-18	2005-03-09	Tatton Technologies Llc	METHODS OF TREATING VIEW DISORDERS
US20030215413A1 (en)	2002-03-22	2003-11-20	L'oreal	Compositions containing stabilized retinoid
US20040097587A1 (en)	2002-03-27	2004-05-20	Arbiser Jack L	Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
US20030228277A1 (en)	2002-03-29	2003-12-11	Gehlsen Kurt R.	Use of ROM production and release inhibitors to treat and prevent intraocular damage
US20040242704A1 (en)	2003-03-14	2004-12-02	University Of Washington, Techtransfer - Invention Licensing	Stabilized mutant opsin proteins
RU2006133300A (ru)	2004-02-17	2008-03-27	Президент Энд Феллоуз Оф Гарвард Колледж (Us)	Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна
US7566808B2 (en)	2004-02-17	2009-07-28	President And Fellows Of Harvard College	Management of ophthalmologic disorders, including macular degeneration
EP1727529B1 (en)	2004-03-17	2016-03-02	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle
EP2397131B1 (en)	2004-06-18	2019-09-11	University of Washington	Retinal derivatives and methods for the use thereof for the treatment of visual disorders
GEP20084520B (en)	2004-06-23	2008-10-27	Sirion Therapeutics Inc	Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
CA2575265A1 (en)	2004-08-18	2006-03-30	Sirion Therapeutics, Inc.	Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders
WO2006039551A2 (en)	2004-09-30	2006-04-13	The Regents Of The University Of California	Local administration of retinoids to treat deficiencies in dark adaptation
EP2687208A1 (en)	2007-09-12	2014-01-22	The Trustees of Columbia University in the City of New York	Compositions and Methods for Treating Macular Degeneration
CA2714530C (en)	2008-02-11	2018-09-25	University Of Washington	Methods for the treatment and prevention of age-related retinal dysfunction

2005
- 2005-06-20 EP EP11163940.7A patent/EP2397131B1/en not_active Expired - Lifetime
- 2005-06-20 RS RS20140036A patent/RS53178B/sr unknown
- 2005-06-20 CN CN201210458886.5A patent/CN102976937B/zh not_active Expired - Fee Related
- 2005-06-20 NZ NZ552080A patent/NZ552080A/en not_active IP Right Cessation
- 2005-06-20 EP EP11163943.1A patent/EP2397132B1/en not_active Expired - Lifetime
- 2005-06-20 KR KR1020137016276A patent/KR101490145B1/ko not_active Expired - Fee Related
- 2005-06-20 ES ES11163940T patent/ES2752924T3/es not_active Expired - Lifetime
- 2005-06-20 MX MX2012003410A patent/MX359668B/es unknown
- 2005-06-20 ES ES11163947.2T patent/ES2644984T3/es not_active Expired - Lifetime
- 2005-06-20 PT PT57735763T patent/PT1765322E/pt unknown
- 2005-06-20 KR KR1020147030120A patent/KR20140140616A/ko not_active Ceased
- 2005-06-20 HR HRP20140116TT patent/HRP20140116T1/hr unknown
- 2005-06-20 RU RU2007101735/04A patent/RU2408578C2/ru active
- 2005-06-20 DK DK05773576.3T patent/DK1765322T3/da active
- 2005-06-20 SI SI200531827T patent/SI1765322T1/sl unknown
- 2005-06-20 EP EP05773576.3A patent/EP1765322B1/en not_active Expired - Lifetime
- 2005-06-20 PL PL11163947T patent/PL2397133T3/pl unknown
- 2005-06-20 SI SI200532176T patent/SI2397133T1/sl unknown
- 2005-06-20 ES ES11163943.1T patent/ES2644981T3/es not_active Expired - Lifetime
- 2005-06-20 CA CA2931917A patent/CA2931917A1/en not_active Abandoned
- 2005-06-20 ZA ZA200700368A patent/ZA200700368B/xx unknown
- 2005-06-20 AU AU2005257997A patent/AU2005257997B2/en not_active Ceased
- 2005-06-20 ES ES05773576.3T patent/ES2443194T3/es not_active Expired - Lifetime
- 2005-06-20 HU HUE11163947A patent/HUE036596T2/hu unknown
- 2005-06-20 EP EP11163947.2A patent/EP2397133B1/en not_active Expired - Lifetime
- 2005-06-20 IN IN9335DEN2012 patent/IN2012DN09335A/en unknown
- 2005-06-20 PL PL05773576T patent/PL1765322T3/pl unknown
- 2005-06-20 MX MXPA06014750A patent/MXPA06014750A/es active IP Right Grant
- 2005-06-20 KR KR1020077001074A patent/KR101337321B1/ko not_active Expired - Fee Related
- 2005-06-20 BR BRPI0511396-2A patent/BRPI0511396B1/pt not_active IP Right Cessation
- 2005-06-20 CA CA2571049A patent/CA2571049C/en not_active Expired - Fee Related
- 2005-06-20 RU RU2010138410/04A patent/RU2554003C2/ru active
- 2005-06-20 US US11/629,875 patent/US7951841B2/en active Active
- 2005-06-20 EP EP11163939.9A patent/EP2397130B1/en not_active Expired - Lifetime
- 2005-06-20 JP JP2007516822A patent/JP5166026B2/ja not_active Expired - Fee Related
- 2005-06-20 KR KR1020127013912A patent/KR101323122B1/ko not_active Expired - Fee Related
- 2005-06-20 LT LTEP11163947.2T patent/LT2397133T/lt unknown
- 2005-06-20 WO PCT/US2005/021812 patent/WO2006002097A2/en not_active Ceased
- 2005-06-20 CN CN2005800240983A patent/CN1988898B/zh not_active Expired - Fee Related
- 2005-06-20 PT PT111639472T patent/PT2397133T/pt unknown
- 2005-06-20 NZ NZ587006A patent/NZ587006A/en not_active IP Right Cessation
- 2005-06-20 DK DK11163947.2T patent/DK2397133T3/en active
2006
- 2006-12-14 IL IL180078A patent/IL180078A/en active IP Right Grant
2007
- 2007-01-17 NO NO20070330A patent/NO339969B1/no not_active IP Right Cessation
2011
- 2011-03-07 US US13/042,308 patent/US9174936B2/en active Active
2012
- 2012-06-28 JP JP2012145562A patent/JP5596749B2/ja not_active Expired - Fee Related
- 2012-09-14 US US13/619,731 patent/US9169204B2/en not_active Expired - Lifetime
- 2012-09-14 US US13/619,631 patent/US9162978B2/en not_active Expired - Lifetime
- 2012-09-14 US US13/619,945 patent/US9403765B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/619,887 patent/US9388130B2/en not_active Expired - Fee Related
- 2012-10-11 IL IL222347A patent/IL222347A/en active IP Right Grant
2013
- 2013-12-30 IL IL230241A patent/IL230241A/en active IP Right Grant
- 2013-12-30 IL IL230242A patent/IL230242A/en active IP Right Grant
2014
- 2014-02-05 CY CY20141100096T patent/CY1114873T1/el unknown
2016
- 2016-07-19 US US15/214,330 patent/US10117845B2/en not_active Expired - Lifetime
2017
- 2017-10-18 CY CY20171101089T patent/CY1119480T1/el unknown
2018
- 2018-10-31 US US16/177,076 patent/US20190167626A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1988898B (zh)	2012-12-26
EP1765322A4 (en)	2008-09-17
EP2397133A2 (en)	2011-12-21
NO20070330L (no)	2007-03-15
KR101337321B1 (ko)	2013-12-06
KR20120062946A (ko)	2012-06-14
US9403765B2 (en)	2016-08-02
KR101323122B1 (ko)	2013-10-30
BRPI0511396B1 (pt)	2021-07-27
JP5596749B2 (ja)	2014-09-24
RU2007101735A (ru)	2008-07-27
RU2408578C2 (ru)	2011-01-10
CY1119480T1 (el)	2018-03-07
US10117845B2 (en)	2018-11-06
EP2397132A3 (en)	2012-07-11
RS53178B (sr)	2014-06-30
IN2012DN09335A (no)	2015-08-21
DK1765322T3 (da)	2014-02-10
ES2644981T3 (es)	2017-12-01
US20130072560A1 (en)	2013-03-21
US20110288170A1 (en)	2011-11-24
JP2012229234A (ja)	2012-11-22
HK1098696A1 (en)	2007-07-27
CA2571049A1 (en)	2006-01-05
IL180078A0 (en)	2007-05-15
JP2008503496A (ja)	2008-02-07
HRP20140116T1 (hr)	2014-03-28
US9388130B2 (en)	2016-07-12
SI2397133T1 (sl)	2017-12-29
CA2931917A1 (en)	2006-01-05
US9174936B2 (en)	2015-11-03
CN102976937A (zh)	2013-03-20
NO339969B1 (no)	2017-02-20
NZ552080A (en)	2011-03-31
DK2397133T3 (en)	2017-10-30
EP2397132B1 (en)	2017-07-26
US7951841B2 (en)	2011-05-31
PL2397133T3 (pl)	2018-01-31
EP1765322A2 (en)	2007-03-28
ES2644984T3 (es)	2017-12-01
IL222347A (en)	2017-08-31
RU2554003C2 (ru)	2015-06-20
BRPI0511396A (pt)	2007-12-04
KR20140140616A (ko)	2014-12-09
MX359668B (es)	2018-10-05
MXPA06014750A (es)	2007-03-21
AU2005257997B2 (en)	2012-04-05
US20080221208A1 (en)	2008-09-11
KR20130079669A (ko)	2013-07-10
NZ587006A (en)	2011-12-22
JP5166026B2 (ja)	2013-03-21
PL1765322T3 (pl)	2014-04-30
CN1988898A (zh)	2007-06-27
CY1114873T1 (el)	2016-12-14
US20130072559A1 (en)	2013-03-21
KR20070026817A (ko)	2007-03-08
EP2397132A2 (en)	2011-12-21
ES2443194T3 (es)	2014-02-18
EP2397131A3 (en)	2012-10-31
IL230242A (en)	2015-10-29
US9169204B2 (en)	2015-10-27
RU2010138410A (ru)	2012-03-27
WO2006002097A2 (en)	2006-01-05
CN102976937B (zh)	2016-12-21
WO2006002097A3 (en)	2006-05-04
PT1765322E (pt)	2014-02-05
PT2397133T (pt)	2017-10-23
IL230241A (en)	2015-06-30
CA2571049C (en)	2016-08-09
EP1765322B1 (en)	2013-11-06
EP2397130A3 (en)	2012-10-31
EP2397130A2 (en)	2011-12-21
US20130072556A1 (en)	2013-03-21
US20170014368A1 (en)	2017-01-19
EP2397133B1 (en)	2017-07-26
US20130079403A1 (en)	2013-03-28
US9162978B2 (en)	2015-10-20
US20190167626A1 (en)	2019-06-06
EP2397131A2 (en)	2011-12-21
IL180078A (en)	2014-01-30
HUE036596T2 (hu)	2018-07-30
ES2752924T3 (es)	2020-04-06
LT2397133T (lt)	2018-01-10
SI1765322T1 (sl)	2014-03-31
AU2005257997A1 (en)	2006-01-05
EP2397131B1 (en)	2019-09-11
EP2397130B1 (en)	2019-04-03
KR101490145B1 (ko)	2015-02-05
EP2397133A3 (en)	2012-07-11

Publication	Publication Date	Title
IL230241A (en)	2015-06-30	Retinal history and methods of using them to treat visual irregularities
ZA200607433B (en)	2009-09-30	Methods and compositions for the treatment of gastroin-testinal disorders
EP1893216A4 (en)	2012-08-08	METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
GB0404693D0 (en)	2004-04-07	Pharmaceutical preparations for the treatment of ocular surface and other disorders
IL178142A0 (en)	2006-12-31	Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
IL183772A0 (en)	2007-09-20	Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
IL189578A0 (en)	2008-08-07	Pyridine derivatives and their use in the treatment of psychotic disorders
AU2003286567A8 (en)	2004-05-13	Methods for the treatment of skin disorders
ZA200806114B (en)	2009-11-25	Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL183656A0 (en)	2007-09-20	Indenyl derivatives and use thereof for the treatment of neurological disorders
IL177772A0 (en)	2006-12-31	Methods and compositions for the treatment of gastrointestinal disorders
LT2444079T (lt)	2017-03-27	Kompozicijos ir būdai, skirti akių sutrikimų gydymui
IL181706A0 (en)	2007-07-04	The treatment of inflammatory disorders and pain
IL175529A0 (en)	2006-09-05	Methods and compositions for the treatment of metabolic disorders
IL187248A0 (en)	2008-02-09	Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
AU2003286741A8 (en)	2004-11-26	Methods and compositions for diagnosis and therapy of parkin-associated disorders
PL371281A1 (en)	2005-06-13	Methods and compositions for the treatment of eye diseases
EP1765331A4 (en)	2007-12-05	METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
EP1539100A4 (en)	2006-01-18	COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
GB0419828D0 (en)	2004-10-13	The treatment of inflammatroy disorders and pain
EP1718329A4 (en)	2008-09-10	METHOD FOR THE TREATMENT OF SKIN DISEASES
ZA200704412B (en)	2008-09-25	Indenyl derivatives and use thereof for the treatment of neurological disorders
HK1107564A (en)	2008-04-11	Indenyl derivatives and use thereof for the treatment of neurological disorders
ZA200805859B (en)	2010-12-29	Methods and compositions for the treatment of gastriontestinal disorders
ZA200801548B (en)	2008-12-31	Pyridine derivatives and their use in the treatment of psychotic disorders